Category - Feature

Feature

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Shanghai-based 111, Inc. (NASDAQ:YI) is helping pioneer the S2B2C model in China as it builds an innovative healthcare platform in the country.

March 2, 2021

Feature

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Feature

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

Achieve Life Sciences (NASDAQ:ACHV) began a pivotal trial in the fourth quarter of 2020 to evaluate cytisinicline, which is derived from the seeds of the laburnum tree, as a potential new treatment for smoking cessation...

February 16, 2021

Feature

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...

February 9, 2021

Feature

ARSTAT developing portfolio of transformational products for women’s health

Closely-held ARSTAT Pharmaceuticals is advancing two patented Phase 3-ready assets: Nuvocept, the first and only oral contraceptive designed for overweight and obese women, and another contraceptive brand, Duacept, as a...

February 2, 2021

Feature

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) expects to report important milestones in its cell therapy clinical programs in dry AMD, cervical spinal cord injury and oncology in 2021, as well as improve its...

January 26, 2021

Feature

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...

January 19, 2021

Feature

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Tarsus Pharmaceuticals (NASDAQ:TARS) launched the Phase 2b/3 Saturn-1 clinical trial in September 2020 with its lead asset, TP-03, as the potential first therapeutic for Demodex blepharitis, where eyelids become red...

January 12, 2021

Feature

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Closely-held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

December 15, 2020

Feature

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Plus Therapeutics (NASDAQ:PSTV) is developing its lead asset, rhenium nanoliposome (RNL), a targeted and potentially more potent radionucleotide therapy, for the treatment of recurrent glioblastoma and several other...

December 8, 2020

Category - Feature

Subscribe